Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2021) 73 AEP433 | DOI: 10.1530/endoabs.73.AEP433

ECE2021 Audio Eposter Presentations General Endocrinology (51 abstracts)

Potential endocrine markers of severity and outcomes in critical patients with COVID-19

Volha Isachkina 1 & Larissa I. Danilova 2


110th City Hospital, Endocrinological, Minsk, Belarus; 2Belarusian Medical Academy of Postgraduate Education, Endocrinological, Minsk, Belarus


Background

The current COVID-19 pandemic is the worst from world infection outbreaks have occurred frequently in the last two decades, and it has led to significant mortality. Although the respiratory system is the most prominent target of SARS-CoV-2, extrapulmonary involvement are important contributors of its morbidity and mortality. A number of symptoms occur in these patients due to the involvement of various endocrine glands. The nervous, endocrine, and immune systems contribute to the response and dynamic adaption to various stresses. Activation of the hypothalamic-pituitary-adrenal axis has been demonstrated in various active critical illnesses. Looking for potential endocrine markers appears to be useful for obtaining information of severity and outcomes in critical patients with COVID-19.

Materials and methods

Prospective descriptive study of critical patients with COVID-19 admitted to the ICU of the hospital from October, 2020, to January, 2021, including hormonal markers and mortality.

Results

In this study, a total 82 of critical patients with COVID-19 in the ICU were enrolled. Dehydroepiandrosterone Sulfate (DHEA-S), total testosterone, SHBG levels were measured in serum of patients. The mean age was 60.4 (standard deviation (SD) 8.7) years, the number of men was 63.4% percent. Regarding outcomes, 46.3% patients with COVID-19 died in the ICU. Mortality consists 38.4% vs 60% in men and women respectively. There are no significant differences in DHEA-S and SHBG levels in died and recovered women with COVID-19. As to men with COVID-19 there are no significant differencse in SHBG levels (21.29 (SD 12.59) nmol/l vs 34.45 (SD 24.53 nmol/l) аnd in DHEA-S levels (59.06 (SD 37.32) mkg/dl vs 62.03 (SD 33.34) mkg/dl) in died and recovered patients respectively. The mean levels of total testosterone were 2.41(SD 1.83) nmol/l in died patients vs 9.87(SD 6.88) nmol/l in recovered ones (P < 0.001).

Conclusion

We expect that the total testosterone may be a useful endocrine marker for poor prognostic outcomes for men with COVID-19 because of its strong association with risk of death.

Volume 73

European Congress of Endocrinology 2021

Online
22 May 2021 - 26 May 2021

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.